What are the top genomics startups to watch in 2026?

Leading genomics startups include Oxford Nanopore Technologies (UK), 23andMe (US), BioNTech (Germany), BGI Genomics (China), Strand Life Sciences (India), Genomics England (UK), Neogene Therapeutics (Netherlands/US), MGI Tech (China), Saudi Genome Project (Saudi Arabia), and Mendelics (Brazil).

Which countries are investing most in genomics?

Major genomics investments come from the US, UK, China, and increasingly the Middle East. Saudi Arabia committed $1.3 billion to its Genome Project, while the UK allocated £200 million to Genomics England. China's BGI Genomics leads global sequencing capacity with facilities expanding across Asia and the Middle East.

What genomics breakthroughs occurred in 2025?

Key 2025 breakthroughs include CRISPR Therapeutics' FDA approval for Casgevy (first gene editing therapy for sickle cell disease), BioNTech's personalized cancer vaccine Phase 2 success, and Oxford Nanopore's expanded clinical diagnostic applications. Venture capital investment in genomics reached $8.7 billion during the year.

How is genomics expanding in emerging markets?

Emerging markets show rapid genomics adoption through companies like Strand Life Sciences (India) processing 500,000+ tests annually, Mendelics leading Latin American diagnostics from Brazil, and regional initiatives like Saudi Genome Project sequencing 100,000 genomes for Middle Eastern population reference databases.

Top 10 Genomics and Genetics Startups to Watch in 2026 in UK, Europe, US, Canada, China, India, Saudi, UAE and Brazil

Q: How large is the global genomics market?

The global genomics market is projected to reach $94.6 billion by 2030, growing at a 16.4% CAGR according to Grand View Research. This growth is driven by declining sequencing costs, AI-powered analysis, expanding therapeutic applications, and increasing adoption of precision medicine approaches across healthcare systems worldwide.

From CRISPR gene editing pioneers to AI-powered drug discovery platforms, these 10 genomics startups are revolutionizing healthcare across the UK, US, Europe, China, India, Middle East and Latin America with breakthrough therapies and precision medicine solutions.

Published: December 6, 2025 By Marcus Rodriguez Category: Genomics

Top 10 Genomics and Genetics Startups to Watch in 2026 in UK, Europe, US, Canada, China, India, Saudi, UAE and Brazil

Executive Summary

Global genomics market projected to reach $94.6 billion by 2030, growing at 16.4% CAGR according to Grand View Research
CRISPR Therapeutics achieves historic FDA approval for Casgevy, the first gene editing therapy for sickle cell disease
China's BGI Genomics processes over 100 million genetic samples, leading global sequencing capacity
Middle East genomics investment surges with Saudi Arabia's $1.3 billion commitment to precision medicine infrastructure
Venture capital investment in genomics startups reached $8.7 billion in 2025, with AI-driven platforms attracting premium valuations

Global Genomics Innovation Reaches Inflection Point The genomics and genetics sector enters 2026 at a pivotal moment, with breakthrough therapies reaching patients and fundamental research translating into commercial applications at unprecedented speed. Grand View Research projects the global genomics market will reach $94.6 billion by 2030, driven by declining sequencing costs, AI-powered analysis, and expanding therapeutic applications. These ten startups represent the vanguard of innovation across established and emerging markets.

1. Oxford Nanopore Technologies Oxford, United Kingdom Oxford Nanopore Technologies revolutionized DNA sequencing with its portable, real-time nanopore technology. The company's MinION and PromethION platforms enable sequencing anywhere—from remote clinics to Antarctic research stations. Reuters reports 2025 revenue exceeded £250 million, with clinical diagnostics representing the fastest-growing segment. Their 2026 roadmap includes enhanced accuracy for clinical applications and expanded partnerships with NHS England for rapid pathogen identification.

2. 23andMe Sunnyvale, California, USA 23andMe has transitioned from consumer genetic testing to therapeutic development, leveraging its database of over 14 million genotyped customers. The company's drug discovery pipeline, developed in partnership with GSK, targets immunology and oncology indications. FierceBiotech reports three programs entered Phase 2 trials in 2025, validating the company's crowdsourced genetic research model.

3. BioNTech Mainz, Germany German pioneer BioNTech...

Read the full article at AI BUSINESS 2.0 NEWS